Indivior Pharmaceuticals, Inc.
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | +18.5% | -16.4% | -18.2% | -17.6% | +22.3% | +13.9% | +21.3% | +8.7% | +4.3% | |
| – | +10.9% | +9.6% | +4.0% | -30.7% | +30.9% | +18.9% | +15.2% | +32.8% | +6.5% | |
| – | +19.5% | -19.5% | -21.8% | -14.7% | +20.7% | +13.0% | +22.5% | +4.1% | +3.8% | |
| – | -14.2% | -31.5% | -17.2% | -24.5% | +30.0% | +42.3% | +56.8% | -7.8% | -9.3% | |
| – | – | – | – | +128.1% | -46.5% | +5.0% | +32.7% | +9.0% | -12.1% | |
| – | +15.7% | -15.6% | -8.1% | +51.2% | -36.1% | +84.3% | +29.4% | -14.0% | -21.3% | |
| – | +25.3% | -25.1% | -43.9% | -187.6% | – | -138.0% | – | – | +728.1% | |
| – | -3.9% | -36.7% | -29.0% | +9.1% | +8.3% | +11.5% | +20.7% | +17.1% | +9.8% | |
| – | +60.4% | +84.5% | -32.2% | -196.1% | – | -146.8% | – | – | +1,607.1% | |
| – | +43.8% | -96.5% | +1,505.3% | -154.3% | – | – | – | – | +163.6% | |
| – | +90.1% | +331.1% | -49.0% | -210.4% | – | -121.5% | – | – | +10,400.0% | |
| – | +192.7% | -29.0% | -25.9% | -153.5% | – | -119.3% | – | – | +261.9% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.